Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Mexico
  4. Mexican Stock Exchange
  5. Genomma Lab Internacional, S.A.B. de C.V.
  6. News
  7. Summary
    LAB B   MX01LA010006

GENOMMA LAB INTERNACIONAL, S.A.B. DE C.V.

(LAB B)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Genomma Lab Internacional SAB de CV : GLI Secures Committed Financing to acquire PBH

04/30/2012 | 02:42pm EDT

Mexico City, April 27th, 2012

GENOMMA LAB INTERNACIONAL SECURES COMMITTED FINANCING TO ACQUIRE PRESTIGE BRANDS HOLDINGS

G e n o m m a L a b I n t e r n a c i o n a l , S . A . B . d e C . V . ("Genomma") (BMV: LAB.B.) reiterated today that it has secured committed financing, subject to customary conditions, from BofA Merrill Lynch and Jefferies Finance LLC to acquire all of the outstanding shares of Prestige Brands Holdings, Inc. ("Prestige") (NYSE: PBH) common stock for $16.60 per share in cash.

Genomma is filing the executed commitment letters with the U.S. Securities and Exchange Commission and the Comisión Nacional Bancaria y de Valores (Mexican National Banking and Securities Commission) and they will be publicly available on Monday, April 30, 2012.

Genomma once again demonstrates that financing for the transaction was never an issue and it has satisfied Prestige's conditions. Genomma once again emphasizes that it is fully prepared at any time to meet with representatives of Prestige to negotiate a mutually acceptable transaction.

Company Description

Genomma Lab Internacional, S.A.B. de C.V. is one of the fastest growing over-the-counter pharmaceutical and personal care products companies in Mexico, offering more than 78 brands, many of which are leaders in their product categories. Genomma has extensive in-house product development capabilities that it uses to develop trusted and established brands. Genomma's top-selling brands occupy a "top-of-mind" position for many consumers. These top- selling brands are supported by a broad portfolio of products which largely target large, high- growth over-the-counter pharmaceutical and personal care markets. For more information, visit

www.genommalab.com.

Contact:

Investor Relations In New York: Grayling USA, Lucía Domville

Tel: +52 (55) 5081 0000 Ext. 5106 Tel: +1 (646) 284-9416

E-mail: inversion@genommalab.com E-mail: genommalab@grayling.com

Forward-looking Statements

This communication may contain certain forward-looking statements and information relating to Genomma that reflect the current views and/or expectations of Genomma and its management with respect to its performance, business and future events. Forward looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like "believe," "anticipate," "expect," "envisages," "will likely result," or any other words or phrases of similar meaning. Such statements are subject to a number of risks, uncertainties and assumptions. These risks and uncertainties include, but are not limited to, the possibility that Genomma will not pursue a transaction with Prestige, the timing to consummate a potential transaction between Genomma and Prestige, the ability and timing to obtain required regulatory approvals, Genomma's ability to realize the synergies contemplated by a potential transaction and Genomma's ability to promptly and effectively integrate the businesses of Prestige and Genomma. We caution you that a number of important factors could cause actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in this communication and in oral statements made by authorized officers of Genomma. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. Except as otherwise provided by law, Genomma undertakes no obligation to update or revise any forward-
looking statements, whether as a result of new information, future events or otherwise.

Important Additional Information

This communication does not constitute an offer to buy or solicitation of an offer to sell any securities. No tender offer for the shares of Prestige has commenced at this time. In connection with the proposed transaction, Genomma may file tender offer documents with the U.S. Securities and Exchange Commission ("SEC"). Any definitive tender offer documents will be mailed to stockholders of Prestige. INVESTORS AND SECURITY HOLDERS OF PRESTIGE ARE URGED TO READ THESE AND OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Investors and security holders of Prestige will be able to obtain free copies of these documents (if and when available) and other documents filed with the SEC by Genomma through the web site maintained by the SEC at
http://www.sec.gov .

Contact:

Investor Relations In New York: Grayling USA, Lucía Domville

Tel: +52 (55) 5081 0000 Ext. 5106 Tel: +1 (646) 284-9416

E-mail: inversion@genommalab.com E-mail: genommalab@grayling.com

distributed by

© Publicnow 2012
All news about GENOMMA LAB INTERNACIONAL, S.A.B. DE C.V.
10/14GENOMMA LAB INTERNACIONAL B DE C : 3Q-2021 Earnings Call Advisory
PU
09/07GENOMMA LAB INTERNACIONAL B DE C : Receives Good Manufacturing Practices (GMP) Certificati..
PU
08/04GENOMMA LAB INTERNACIONAL B DE C : External Auditor Ratification
PU
07/28GENOMMA LAB INTERNACIONAL B DE C : Q2 2021 Earnings Release
PU
07/28Genomma Lab Internacional, S.A.B. De C.V. Reports Earnings Results for the Second Quart..
CI
07/28TRANCHE UPDATE ON GENOMMA LAB INTERN : LAB B)'s Equity Buyback Plan announced on March 20,..
CI
07/13GENOMMA LAB INTERNACIONAL B DE C : 2Q-2021 Earnings Call Advisory
PU
04/28TRANCHE UPDATE ON GENOMMA LAB INTERN : LAB B)'s Equity Buyback Plan announced on March 20,..
CI
04/28Genomma Lab Internacional, S.A.B. De C.V. Reports Earnings Results for the First Quarte..
CI
02/24TRANCHE UPDATE ON GENOMMA LAB INTERN : LAB B)'s Equity Buyback Plan announced on March 20,..
CI
More news
Financials
Sales 2021 14 736 M 729 M 729 M
Net income 2021 1 616 M 79,9 M 79,9 M
Net Debt 2021 3 693 M 183 M 183 M
P/E ratio 2021 12,7x
Yield 2021 1,47%
Capitalization 19 558 M 969 M 967 M
EV / Sales 2021 1,58x
EV / Sales 2022 1,39x
Nbr of Employees 1 451
Free-Float 70,9%
Chart GENOMMA LAB INTERNACIONAL, S.A.B. DE C.V.
Duration : Period :
Genomma Lab Internacional, S.A.B. de C.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GENOMMA LAB INTERNACIONAL, S.A.B. DE C.V.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 19,40 MXN
Average target price 26,08 MXN
Spread / Average Target 34,4%
EPS Revisions
Managers and Directors
Jorge Luis Brake Valderrama Chief Executive Officer
Antonio Zamora Galland Vice President-Administration & Finance
Rodrigo Alonso Herrera Aspra Chairman
Marco Sparvieri Chief Operating Officer & Executive Vice President
Juan Alonso Independent Director
Sector and Competitors
1st jan.Capi. (M$)
GENOMMA LAB INTERNACIONAL, S.A.B. DE C.V.2.97%969
JOHNSON & JOHNSON4.07%431 148
ROCHE HOLDING AG13.98%333 101
PFIZER, INC.14.34%239 966
NOVO NORDISK A/S56.26%238 738
ELI LILLY AND COMPANY44.35%220 952